KIRAN Corporation is pleased to announce the signing of a capital partnership agreement with ChemiTeras Co., Ltd., a company that comprehensively conducts research, sales, and rightsization of self-developed drugs based on a global presence.

■ About Chemiteras, Inc.

Chemiteras Co., Ltd. collaborates with the Nobel Prize Committee in Physiology or Medicine and has advisory directors from the Karolinska Institute, one of the world’s largest medical research institutions established in Sweden in 1810. Currently, they are conducting research and development on dementia. Within Japan, they plan to start clinical trials by the end of the year and aim to verify the effectiveness for various diseases, starting with rare diseases like mitochondrial disorders.

■ Vision of ChemiTeras Co., Ltd.

Chemiteras aims to envision beyond “treatment of rare diseases” and strives to achieve the realization of “prevention of diseases” by developing its own therapeutic drugs, utilizing technology for compound semiconductor manufacturing equipment, and managing and utilizing intellectual property. The company’s platform “UNIPLAT,” which connects researchers, research, and businesses worldwide, has been recognized as an SDGs project and was featured in the G20 report in November 2020.

Regarding the G20 report (pages 156-157) featuring the Chemiteras proposal.

For more information, please visit：https://unify21.com/

・Company Name：Chemiteras, Inc.

・CEO：Tsunenori Terada

・Address：3-24-5 Shinyokohama, Kouhoku-ku, Yokohama, Kanagawa, Japan

・Business：Research and development of new pharmaceuticals, Rightsization

・Website： https://chemiteras.com/jp